

Medicines Formulary Assessments

- **Liraglutide (Saxenda®)** for obesity in patients aged 12 and over—Added to both Formularies (**Red**)
- **Liraglutide (Victoza®)** for Type 2 diabetes in patients aged 10 and over—Added to both Formularies (**Red**).

The Emollients section of the Formularies have been reviewed with the following major changes (**Green** unless otherwise stated):-

- Addition of Epimax® range as cost-effective choice (joint first line with Zero® range)
- Removal of all QV® products (high cost with no unique clinical benefit identified over other more cost-effective emollients)
- Removal of QV wash® in line with NHSE guidance – patients to purchase in place of regular shower gels / bath products where desired
- Addition of Adex gel® (**Amber/Amber 1** restricted), for use in eczema and psoriasis where tacrolimus/pimecrolimus or steroids are contraindicated/inappropriate or as alternative to frequent Dermol® use
- Replacement of Dermacool® products with Menthoderm® or Arjun® for use where itching remains problematic despite normal emollient use and where a cooling effect useful. Dermacool highest cost in this category and also contains SLS which may cause skin irritation. Menthoderm also available as a pump, which is recommended to reduce contamination.
- Addition of urea/lauromacrogol agents e.g. E45 itch relief restricted for use where normal emollients fail to relieve itching
- Flexitol urea added as a replacement of Eucerin intensive (discontinued) for use in cracked diabetic feet only.

- **Melatonin tablets (Adaflex®)** for insomnia associated with attention deficit hyperactivity disorder in patients aged 6-17 years old - Added to the Formularies (**Amber SCG/Amber 1**) - cost-effective 1st line choice

- **Metformin oral powder sachets** for Type 2 diabetes —Added to the Formularies (**Green**) - cost effective preparation vs liquids for patients with swallowing difficulties. NB: Each 500mg dose must be reconstituted in 150mL water—consider fluid volume for relevant patients

- **Latanoprost/Timolol Preservative free eye drops (Fixapost®)** for glaucoma - added to the Formularies (**Amber/Amber 1**). Restricted for use where preservative containing eye drops are not tolerated/appropriate.

- **Indapamide 1.5mg modified release tablets** for hypertension—Removed from Beds/Luton formulary following review. Existing patients may remain on therapy.
- **Tiotropium 18microgram inhaler (Tiogiva®)** for COPD—(**Green**) cost effective and preferred choice of inhaler vs Spiriva® handihaler.
- **Budelin Novolizer®** and **Budesonide Easyhaler®** added (**Green**) as low carbon options for treatment of asthma.
- **Phenazone and lidocaine ear drops (Otigo®)** for otitis media— Moved to **Green** on the Formularies. Restricted: Not to be co-prescribed with antimicrobials. Use only as antimicrobial sparing prescription.
- **Symbicort 200/6 turbobaler**—is now licensed as a reliever in patients aged 12 and above with mild asthma.
- **Salofalk® suppositories and foam enema** added to Beds/Luton to align with MK (**Green**)—cost-effective choice vs Pentasa® brand.

Other Formulary updates:

- The Black and RedRed designations have now been retired and replaced with **DNP – Do not prescribe**. This forms part of a major project by BLMK ICB to align both Formularies. After the review, dicyclorine liquid, dosulepin and pseudoephedrine were removed from MKF to align with national recommendations.
- **Pholcodine** has been withdrawn from the UK market for safety reasons—Formulary entries have been updated to reflect this. See [MHRA Alert](#) for more details.
- **Femseven Sequi, somatuline LA** and **Ketovite** have been discontinued.
- All **wound care products** have been hidden from the medicines Formulary. For all wound care products in Bed/Luton, please refer to the [Wound Care Formulary](#). For wound care guidance in Milton Keynes please refer to [Practice Nursing wound care Formulary](#) and the [Nursing Homes wound care Formulary](#).